血清肿瘤标志物联合检测在肺癌诊断中的应用

目的：探讨血清19片段角蛋白((2YFRA21-1)、神经元特异性烯醇化酶(NSE)、癌胚抗原((CEA)、β2微球蛋白(β2-MG)联合检测提高肺癌的阳性率，为临床提供早期诊断、治疗的依据。方法：采用电化学发光和免疫比浊法检测155例肺癌、72例肺良性疾病和50例正常人血清CYFRA21-1、NSE、CEA和β2-MG的水平。结果：肺癌4项标志物联合检测阳性率明显高于肺良性疾病组和健康人正常对照组，其中CYFRA21-1阳性率以鳞癌最高(77．7％)，与其它型肺癌存在显著差异。NSE阳性率以小细胞性肺癌最高(78．4％)，与其它型肺癌存在显著差异。结论：CYFRA21-1、NSE、CEA、β2-MG是诊断肺癌有价值的肿瘤标志物组合，有助于提高肺癌诊断的阳性率、特异性和准确性。     

用神经网络法预测药物在体透过人皮肤的渗透性

目的：预测药物在体透过人皮肤的渗透性。方法：以正辛醇／水分配系数(logP)、分子体积(V)、氢键酸度(∑β2^H)和氢键碱度(∑β2^H)等理化参数作为输入层神经元，以药物在一定时间内在体透过人皮肤的透过比的对数值(R，透过量／未透过量)作为输出层神经元，建立起合适的BP(Back—propagation)神经网络。结果：17个药物在一定时间内在体透过人皮肤的透过比的神经网络计算值和实测值均相当符合。结论：用BP神经网络法可以较好地预测药物在体透过人皮肤的渗透性。     

Relationship between apoptosis and proliferation in secondary tumors of the brain

A correlation between apoptosis and proliferation in astrocytomas and oligodendrogliomas, but not in glioblastomas, has been previously reported. An index for apoptosis and proliferation was established for each tumor in a series of 20 brain metastases, and its correlation was studied using the Spearman rank correlation test. Apoptosis index (AI) ranged between 1 and 78% (mean ± SD: 11.48 ± 16.4). Proliferation index (PI) ranged between 2.4 and 21% (mean ± SD: 8.23 ± 4.8). When the relationship between AI and PI was studied, a clear correlation was found (r: 0.8965, 95% CI: 0.74–0.95; P < 0.0001). Therefore, it is concluded that a clear correlation exists between proliferation and apoptosis in secondary tumors of the brain.     

抑制素(Inhibin)的研究 Ⅰ.人精液抑制素的制备及其生物学特性

本文报道人精液抑制素的制备及其生物学特性。收集的新鲜人精液经乙醇沉淀和丙酮冲洗,获得的粗提物经Sephadex G100处理,产生具有高活性抑制素hP2组分。应用hP2测定使去势雄性大鼠增高的血清FSH水平降低。其生物特性:hP2的生物活性按单位重量计算为粗提物的10倍以上,包含16种氨基酸,通过SDS-PAGE计算分子量为11,500道尔顿。     

生物学标志在产肠毒素性大肠埃希菌同源克隆鉴定中的应用

目的研究多方法、多生物学标志在产肠毒素性大肠埃希菌同源克隆鉴定中的作用。方法在毒力基因检测和分型基础上，首次采用质粒分析法结合多位点酶电泳法，对ＥＴＥＣ同源克隆进行了综合研究。结果７个毒力基因型的２０６株散发ＥＴＥＣ菌株经质粒图谱分型后，共可分成９３个质粒型，有１４０株ＥＴＥＣ具有独特的基因型；进一步用多位点酶电泳分型，２０６株ＥＴＥＣ可被分成１４８个ＥＴ型，３种方法综合，共有１９０株ＥＴＥＣ具有独特的基因型。结论多方法、多生物学标志在同源克隆鉴定中能提供更多、更可靠的信息。     

双抗体夹心法检测胆管癌患者血清中胆管癌相关抗原的临床意义

胆管癌相关抗原（ＣＣＲＡ）是我们从人胆管癌组织中提取的一种新的肿瘤标志物。建立了检测ＣＣＲＡ的ＥＬＩＳＡ方法，检测了４０例正常人及２６８例良恶性疾病病人血清的ＣＣＲＡ浓度，后者包括胆管癌３６例、原发性肝癌４０例、胰腺癌２６例、胃癌３１例、结直肠癌３４例、肺癌１７例、肝硬变２０例、胆石症４０例及胃溃疡２４例。结果显示：４０例正常对照组的血清ＣＣＲＡ浓度为（１４．３８±７．３４）μｇ／ｍｌ（ｘ±ｓ），正常上限为２８．９５μｇ／ｍｌ（ｘ＋２ｓ）；血清ＣＣＲＡ诊断胆管癌的敏感性是７７．７８％，明显高于其它肿瘤组（０～２５）％（Ｐ＜０．００１），特异性是（７５～１００）％。认为对于胆管癌的诊断，ＣＣＲＡ可能是一种较特异的肿瘤相关抗原。     

DWI、IVIM参数与脑胶质瘤患儿肿瘤标志物水平相关性

目的 探究扩散加权成像(diffusion weighted imaging, DWI)、体素不相干运动扩散加权成像(diffusion-weighted imaging of voxel incoherent motion, IVIM)参数与脑胶质瘤患儿肿瘤标志物水平相关性及诊断价值。方法 选取于我院进行诊断的疑似脑胶质瘤患儿89例,以病理检查为金标准,最终确诊脑胶质瘤患儿62例为观察组,其余27例为对照组。所有研究对象均进行DWI技术、IVIM技术检查,酶联免疫吸附实验法检测糖链抗原125(carbohydrate antigen 125,CA125)、表皮生长因子(epidermal growth factor, EGF)、癌胚抗原(carcinoembryonic antigen, CEA)水平,对比不同病情患儿表观弥散系数(apparent dispersion coefficient, ADC)、相对脑血容量(relative cerebral blood volume, rCBV)、真实水分子弥散系数(true water molecular dispersion coe...     

分子标记在医学蠕虫遗传多态性研究中的应用

医学蠕虫引起的人兽共患寄生虫病严重危害人类健康。对医学蠕虫进行遗传多态性研究,不仅可以了解其种群的生物学特性和遗传结构,而且有助于揭示它们如何适应寄生环境,从而有助于对寄生虫病流行规律的认识,加深对寄生虫病精准防控的理解。随着分子生物学的发展,DNA条形码、简单序列重复、单核苷酸多态性标记等分子标记已被广泛应用于研究寄生虫个体间及群体间的遗传关系,揭示寄生虫种群的遗传变异、物种的起源进化等。本文对目前常用的三类分子标记在医学蠕虫遗传多态性研究中的应用进行系统综述,以期为相关研究奠定基础。     

The genetic fine structure of nonsense suppressors in Schizosaccharomyces pombe

Summary Meiotic fine-structure maps of two efficient UGA suppressors of Schizosaccharomyces pombe which are known (sup8-e) or inferred (sup10-e) to code for two leucine tRNAs carrying the mutant anticodon U^*CA (Kohli et al. 1979, 1980a, b; Wetzel et al. 1979; Mao et al. 1981) are presented. In both cases, the recombination frequencies given by the primary site of the anticodon mutation fitwell into the map defined by the sites of a number of inactivating secondary mutations. This contrasts the corresponding situation found in the serine tRNA genes sup3 and sup9 where the anticodon site exhibits a specific marker effect which strongly increases recombination frequencies in crosses with all revertant sites, due to a decrease in the efficiency of excision repair of base-pair mismatches whenever the anticodon site is included in hybrid-DNA (Hofer et al. 1979; Munz and Leupold 1979; Thuriaux et al. 1980). A pronounced specific marker effect which leads to a several fold increase of the recombination frequencies over those expected is observed, however, at one of the secondary inactivating sites mapping in the leucine tRNA gene sup8.     

Currently used nucleic acid amplification tests for the detection of viruses and atypicals in acute respiratory infections

For the detection of respiratory viruses conventional culture techniques are still considered as the gold standard. However, results are mostly available too late to have an impact on patient management. The latest developments include appropriate DNA- and RNA-based amplification techniques (both NASBA and PCR) for the detection of an extended number of agents responsible for LRTI. Real time amplification, the latest technical progress, produces, within a considerable shorter time, results with a lower risk of false positives. As results can be obtained within the same day, patient management with appropriate therapy or reduction of unnecessary antibiotic therapy in LRTI will be possible. A number of technical aspects of these amplification assays, and their advantages are discussed.The availability and use of these new diagnostic tools in virology has contributed to a better understanding of the role of respiratory viruses in LRTI. The increasing importance of the viral agents, Mycoplasma pneumoniae and Chlamydophila pneumoniae in ARI is illustrated. A great proportion of ARI are caused by viruses, but their relative importance depends on the spectrum of agents covered by the diagnostic techniques and on the populations studied, the geographical location and the season. The discovery of new viruses is ongoing; examples are the hMPV and the increasing number of coronaviruses. Indications for the use of these rapid techniques in different clinical situations are discussed. Depending on the possibilities, the laboratory could optimize its diagnostic strategy by applying a combination of immunofluorescence for the detection of RSV an IFL, and a combination of real-time amplification tests for other respiratory viruses and the atypical agents. When implementing a strategy, a compromise between sensitivity, clinical utility, turn around time and cost will have to be found.